GLAND PHARMA LIMITED
Latest filings
Next results: Fri, 6 Nov · Financial Results- USFDA closes Dundigal inspection with four procedural observations · Regulatory & Legal
- Gland Pharma schedules Q2 FY27 earnings call · Board & Shareholder Meetings
- Gland Pharma to approve September 2026 quarterly results · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Makes complex injectable pharmaceutical products for global markets, with a growing contract development and manufacturing (CDMO) business that accounted for 46% of consolidated revenues in FY26 and grew 28% year-over-year. The base injectables/generics business covers the balance of revenue; the company launched 31 products in the US in FY26, including 5 in Q4 alone, and recently won USFDA approval for Sugammadex Injection. The European CDMO arm, Cenexi, returned to EBITDA positive in Q4 FY26, delivering EUR 182 million in FY26 revenue (+11% YoY). Operations span six domestic plants in India and four international plants, and 88.44% of revenue comes from exports across around 60 countries. The biggest cost line is materials and consumables at 34.8% of revenue, followed by employee costs at 25.3%, with capex planned at INR 500 crore in FY27 and INR 2,000 crore over the next five years.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from GLAND PHARMA LIMITED's filed financials and exchange disclosures
What does GLAND PHARMA LIMITED do?
GLAND PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GLAND.
Is GLAND PHARMA LIMITED profitable?
Yes. Over the trailing twelve months GLAND PHARMA LIMITED reported a net profit of ₹1,129 Cr on revenue of ₹6,725 Cr.
Does GLAND PHARMA LIMITED pay a dividend?
Yes. The dividend yield is 0.61% at the current price. It paid out 29% of its profit as dividend in FY26.
Is GLAND PHARMA LIMITED debt-free?
On a net basis, yes. It reported borrowings of ₹243 Cr on its 31 Mar 2026 balance sheet, but holds ₹3,116 Cr more cash than debt.
Is GLAND PHARMA LIMITED expensive compared with its peers?
On trailing P/E, GLAND PHARMA LIMITED ranks 109 of 158 in Pharmaceuticals — cheaper than 31% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the GLAND PHARMA LIMITED share price move in a day?
On a typical session GLAND PHARMA LIMITED moves 1.01% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are GLAND PHARMA LIMITED's next results?
Financial Results on Fri, 6 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track GLAND PHARMA LIMITED's announcements?
Every NSE and BSE filing by GLAND PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.